<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство и гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0300-9092</issn><issn publication-format="electronic">2412-5679</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">248892</article-id><article-id pub-id-type="doi">10.18565/aig.2020.5.105-12</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE EFFECTIVENESS OF TARGETED INTERFERON REPLACEMENT THERAPY IN PATIENTS WITH EXTRAGENITAL ENDOMETRIOSIS</article-title><trans-title-group xml:lang="ru"><trans-title>ЭФФЕКТИВНОСТЬ ПРИМЕНЕНИЯ ТАРГЕТНОЙ ИНТЕРФЕРОНЗАМЕСТИТЕЛЬНОЙ ТЕРАПИИ У БОЛЬНЫХ НАРУЖНЫМ ГЕНИТАЛЬНЫМ ЭНДОМЕТРИОЗОМ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>YARMOLINSKAYA</surname><given-names>Mariya I.</given-names></name><name xml:lang="ru"><surname>ЯРМОЛИНСКАЯ</surname><given-names>М. И</given-names></name></name-alternatives><bio xml:lang="en"><p>Dr.Med.Sci., Professor of the RAS, Head of the Department of Gynecology and Endocrinology, Head of the Center of Diagnosis and Treatment of Endometriosis, D.O. Ott Research Institute for Obstetrics and Gynecology, Professor at the Department of Obstetrics and Gynecology, I.I. Mechnikov North-Western State Medical University</p></bio><bio xml:lang="ru"><p>д.м.н., профессор РАН, руководитель отдела гинекологии и эндокринологии, руководитель «Центра диагностики и лечения эндометриоза» ФГБНУ «НИИ АГиР им. ДО. Отта», профессор кафедры акушерства и гинекологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова» Минздрава России.</p></bio><email>m.yarmolinskaya@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DURNEVA</surname><given-names>Elena I.</given-names></name><name xml:lang="ru"><surname>ДУРНЕВА</surname><given-names>Елена Игоревна</given-names></name></name-alternatives><bio xml:lang="en"><p>Ph.D. Student at the Department of Gynecology and Endocrinology</p></bio><bio xml:lang="ru"><p>аспирант отдела гинекологии и эндокринологии</p></bio><email>elenadurnevai303@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SEL'KOV</surname><given-names>Sergey A.</given-names></name><name xml:lang="ru"><surname>СЕЛЬКОВ</surname><given-names>Сергей Алексеевич</given-names></name></name-alternatives><bio xml:lang="en"><p>Merited Scholar of the Russian Federation, Professor, Head of the Department of Immunology and Intercellular Interactions</p></bio><bio xml:lang="ru"><p>заслуженный деятель науки РФ, профессор, заведующий отделом иммунологии и межклеточных взаимодействий</p></bio><email>selkovsa@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>CHEPANOV</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>ЧЕПАНОВ</surname><given-names>Сергей Владимирович</given-names></name></name-alternatives><bio xml:lang="en"><p>Ph.D., Senior Researcher at the Proteomic Immunoregulation Group, Department of Immunology and Intercellular Interactions</p></bio><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник группы протеомной иммунорегуляции отдела иммунологии и межклеточных взаимодействий</p></bio><email>chepanovsv@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SELYUTIN</surname><given-names>Alexander V.</given-names></name><name xml:lang="ru"><surname>СЕЛЮТИН</surname><given-names>Александр Васильевич</given-names></name></name-alternatives><bio xml:lang="en"><p>Ph.D. (biol.sci.), Senior Researcher at the Immunology Laboratory with AIDS Diagnostics Group, Department of Immunology and Intercellular Interactions</p></bio><bio xml:lang="ru"><p>к.б.н., старший научный сотрудник лаборатории иммунологии с группой по диагностике СПИД, отдел иммунологии и межклеточных взаимодействий</p></bio><email>a_selutin@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SOKOLOV</surname><given-names>Dmitriy I.</given-names></name><name xml:lang="ru"><surname>СОКОЛОВ</surname><given-names>Дмитрий Игоревич</given-names></name></name-alternatives><bio xml:lang="en"><p>Dr.Biol.Sci., Head of the Laboratory of Intercellular Interactions, Department of Immunology and Intercellular Interactions</p></bio><bio xml:lang="ru"><p>д.б.н., заведующий лабораторией межклеточных взаимодействий, отдел иммунологии и межклеточных взаимодействий</p></bio><email>falcojugger@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">D.O. Ott Research Institute for Obstetrics and Gynecology of the RAS</institution></aff><aff><institution xml:lang="ru">ФГБНУ «НИИ акушерства, гинекологии и репродуктологии им. Д.О. Отта»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.I. Mechnikov North-Western State Medical University of Minzdrav of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2020</year></pub-date><issue>5</issue><issue-title xml:lang="en">NO5 (2020)</issue-title><issue-title xml:lang="ru">№5 (2020)</issue-title><fpage>105</fpage><lpage>112</lpage><history><date date-type="received" iso-8601-date="2023-02-18"><day>18</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО «Бионика Медиа»</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0300-9092/article/view/248892">https://journals.eco-vector.com/0300-9092/article/view/248892</self-uri><abstract xml:lang="en"><p>Aim. To compare the effectiveness of extragenital endometriosis (EGE) treatment regimens with and without interferon-alpha-2b (IFN-α2b). Materials and methods. The study comprised 46patients with stage I and II EGE. Twenty-one patients in the study group received standard six months therapy with gonadotropin-releasing hormone agonists (GnRHa) concurrently with IFN-α2b, while 25patients in the control group were administered GnRHa monotherapy. Before surgery and six months after the treatment initiation, the composition of the lymphocyte subpopulations in the peripheral blood was determined by flow cytofluorometry. Results. Compared to the control group, combination therapy of patients with EGE using IFN-α2b was associated with an increase in peripheral blood T and B lymphocyte counts, preservation of NK cell activity with a decrease in their number. Conclusion. The effect ofIFN-α2b as part of combination therapy on the composition of the lymphocyte subpopulations is associated with better immune response toward heterotopic endometrial cells and protective effect against recurrent endometriosis, compared with monotherapy.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Оценить эффективность применения интерферона альфа-2b (IFN-α2b) в комплексной терапии заболевания по сравнению со стандартной схемой лечения. Материалы и методы. В исследование вошли 46 пациенток с диагнозом наружный генитальный эндометриоз (НГЭ) (I и II стадии). Основная группа представлена 21 пациенткой, которые получали стандартную терапию агонистами гонадотропин-рилизинг-гормона (аГнРГ) в течение 6 месяцев в сочетании с IFN-α2b, а пациенты группы сравнения (25 больных) получали монотерапию аГнРГ. Перед оперативным вмешательством и через 6месяцев после начала лечения в периферической крови определяли субпопуляционный состав лимфоцитов методом проточной цитофлуориметрии. Результаты. Комбинированное лечение пациенток с НГЭ с применением IFN-α2b сопровождалось увеличением в периферической крови количества Т- и В-лимфоцитов, сохранением активности NK-клеток, наряду со снижением их количества относительно группы сравнения. Заключение. Влияние IFN-α2b в составе комплексной терапии на субпопуляционный состав лимфоцитов свидетельствует в пользу реализации адекватного иммунного ответа в отношении клеток эндометриоидных гетеротопий, а также о возможном протективном действии в отношении возникновения рецидивов по сравнению с монотерапией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>endometriosis</kwd><kwd>interferon</kwd><kwd>T-lymphocytes</kwd><kwd>B-lymphocytes</kwd><kwd>NK cells</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эндометриоз</kwd><kwd>интерферон</kwd><kwd>Т-лимфоциты</kwd><kwd>В- лимфоциты</kwd><kwd>NK-клетки</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bulun S.E., Yilmaz B.D., Sison C., Miyazaki K., Bernardi L., Liu S. et al. Endometriosis. Endocr. Rev. 2019; 40(4): 1048-9. https://dx.doi.org/10.1210/ er.2018-00242.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Culley L., Law C., Hudson N., Denny E., Mitchell H., Baumgarten M. et al. The social and psychological impact of endometriosis on women’s lives: a critical narrative review. Hum. Reprod. Update. 2013; 19(6): 625-39. https://dx.doi. org/10.1093/humupd/dmt027.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Symons L.K., Miller J.E., Kay V.R., Marks R.M., Liblik K., Koti M. et al. The immunopathophysiology of endometriosis. Trends Mol. Med. 2018; 24(9): 748-62. https://dx.doi.org/10.1016/j.molmed. 2018.07.004.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Osuga Y., Koga K., Hirota Y., Hirata T., Yoshino O., Taketani Y. Lymphocytes in endometriosis. Am. J. Reprod. Immunol. 2011; 65(1): 1-10. https://dx.doi. org/10.1111/j.1600-0897.2010.00887.x.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sourial S., Tempest N., Hapangama D.K. Theories on the pathogenesis of endometriosis. Int. J. Reprod. Med. 2014; 2014: 179515. https://dx.doi. org/10.1155/2014/179515.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Dicitore A., Castiglioni S., Saronni D., Gentilini D., Borghi M.O., Stabile S. et al. Effects of human recombinant type I IFNs (IFN-alpha2b and IFN-beta1a) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis: A preliminary study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018; 230: 192-8. https://dx.doi.org/10.1016/j. ejogrb.2018.10.004.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012; 12(2): 125-35. https://dx.doi. org/10.1038/nri3133.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ingelmo J.M., Quereda F., Acien P. Effect of human interferon-alpha-2b on experimental endometriosis in rats: comparison between short and long series of treatment. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 167(2): 190-3. https:// dx.doi.org/10.1016/j.ejogrb.2012.11.019.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Badawy S.Z., Etman A., Cuenca V., Montante A., Kaufman L. Effect of interferon alpha-2b on endometrioma cells in vitro. Obstet. Gynecol. 2001; 98(3): 417-20. https://dx.doi.org/10.1016/S0029-7844(01)01395-3.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ingelmo J.M., Quereda F., Acien P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a murine model. Fertil. Steril. 1999; 71(5): 907-11. https://dx.doi.org/10.1016/ S0015-0282(99)00087-4.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Павлов Р.В., Сельков С.А. Эффективность внутрибрюшинного применения интерферона в терапии экспериментального эндометриоза у крыс. Медицинская иммунология. 2006; 8(5-8): 721-6.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ali A.F.M., Fateen B., Ezzet A., Badawy H., Ramadan A., El-tobge A. Laparoscopic intraperitoneal injection of human interferon-a2b in the treatment of pelvic endometriosis: a new modality. Obstet. Gynecol. 2000; 95(4, Suppl. 1): 547--8. https://dx.doi.org/10.1016/S0029-7844(00)00684-0.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Acien P., Quereda F., Campos A., Gomez-Torres M.J., Velasco I., Gutierrez M. Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil. Steril. 2002; 78(4): 705-11. https://dx.doi.org/10.1016/S0015-0282(02) 03330-7.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Дурнева Е.И., Ярмолинская М.И., Соколов Д.И., Сельков С.А., Селютин А.В. Клиническая эффективность и патогенетическое обоснование применения человеческого рекомбинантного интерферона альфа-2 b в комбинированном лечении больных наружным генитальным эндометриозом. Вопросы гинекологии, акушерства и перинатологии. 2019; 18(2): 61-8. https://dx.doi.org/10.20953/1726-1678-2019-2-61-68.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods. 2004; 294(1-2): 15-22. https://dx.doi.org/10.1016/j.jim.2004. 08.008.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Dunselman G.A., Vermeulen N., Becker C., Calhaz-Jorge C., D’Hooghe T., De Bie B. et al. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014; 29(3): 400-12. https//dx.doi.org/10.1093/humrep/det457.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bishop L.A. Management of chronic pelvic pain. Clin. Obstet. Gynecol. 2017; 60(3): 524-30. https://dx.doi.org/10.1097/GRF.0000000000000299.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Акинфиева О.В., Бубнова Л.Н. NKT-клетки: характерные свойства и функциональная значимость для регуляции иммунного ответа. Онкогематология. 2010; 4: 39-47.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Negishi Y., Takahashi H., Kuwabara Y., Takeshita T. Innate immune cells in reproduction. J. Obstet. Gynaecol. Res. 2018; 44(11): 2025-36. https://dx.doi. org/10.1111/jog.13759.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Spaccarelli N., Rook A. The use of interferons in the treatment of cutaneous T-cell lymphoma. Dermatol. Clin. 2015; 33(4): 731-45. https://dx.doi. org/10.1016/j.det.2015.05.008.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lapenta C., Donati S., Spadaro F., Castaldo P., Belardelli F., Cox M.C., Santini S.M. NK cell activation in the antitumor response induced by IFN-alpha dendritic cells loaded with apoptotic cells from follicular lymphoma patients. J. Immunol. 2016; 197(3): 795-806. https://dx.doi.org/10.4049/ jimmunol.1600262.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Бекетова Г.В. Интерфероны в лечении острых респираторных инфекций у детей. Лики Украины. 2011; 3: 106-9.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Thiruchelvam U, Wingfield M., O’Farrelly C. Natural killer cells: key players in endometriosis. Am. J. Reprod. Immunol. 2015; 74(4): 291-301. https://dx.doi. org/10.1111/aji.12408.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Riccio L., Santulli P., Marcellin L., Abrao M.S., Batteux F., Chapron C. Immunology of endometriosis. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 50: 39-49. https://dx.doi.org/10.1016/j.bpobgyn.2018.01.010.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. СПб.: Эко-Вектор; 2017: 150-1.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Wong K.H., Simon J.A. In vitro effect of gonadotropin-releasing hormone agonist on natural killer cell cytolysis in women with and without endometriosis. Am. J. Obstet. Gynecol. 2014; 190(1): 44-9. https://dx.doi.org/10.1016/ j.ajog.2003.08.032.</mixed-citation></ref></ref-list></back></article>
